Institute for Complex Systems and Mathematical Biology (ICSMB)
Room 341, Meston Building, Meston Walk
King's College, Old Aberdeen
University of Aberdeen
Aberdeen AB24 3UE
UK
Significant dose-dependent reduction in neurofilament light chain concentration in plasma with oral tau aggregation inhibitor hydromethylthionine mesylate
Wischik, C. M., Schelter, B., Penny, L. K., Miller, S., Stefanacci, R., Heslegrave, A., Zetterberg, H.
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate
Wischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., Schelter, B. O.
Journal of Prevention of Alzheimer's Disease, vol. 9, pp. 780-790
Long-term hydromethylthionine treatment is associated with delayed clinical onset and slowing of cerebral atrophy in a pre-symptomatic P301S MAPT mutation carrier
Bentham, P., Staff, R. T., Schelter, B. O., Shiells, H., Harrington, C. R., Wischik, C. M.
Journal of Alzheimer's Disease, vol. 83, no. 3, pp. 1017-1023
Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia
Shiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., Hammel, J., Vuksanovic, V., Staff, R. T., Murray, A. D., Bracoud, L., Wischik, D. J., Riedel, G., Gauthier, S., Jia, J., Moebius, H. J., Hardlund, J., Kipps, C. M., Kook, K., Storey, J. M. D., Harrington, C. R., Wischik, C. M.
Journal of Alzheimer's Disease, vol. 75, no. 2, pp. 501-519